Impact of Minimally Invasive Surfactant Therapy in Preterm Infants at 29-32 Weeks Gestation
Overview
Affiliations
Background: Most preterm infants born at 29-32 weeks gestation now avoid intubation in early life, and thus lack the usual conduit through which exogenous surfactant is given if needed.
Objective: The aim of this work was to examine whether a technique of minimally invasive surfactant therapy used selectively at 29-32 weeks gestation would improve outcomes.
Methods: We studied the impact of selective administration of surfactant (poractant alfa 100-200 mg/kg) by thin catheter in infants with respiratory distress syndrome on continuous positive airway pressure (CPAP). The threshold for consideration of treatment was CPAP ≥7 cm H2O and FiO2 ≥0.35 prior to 24 h of life. In-hospital outcomes were compared before and after introducing minimally invasive surfactant therapy (epochs 1 and 2, respectively).
Results: During epoch 2, of 266 infants commencing CPAP, 51 (19%) reached the treatment threshold. Thirty-seven infants received surfactant via thin catheter, and CPAP failure was avoided in 34 of these (92%). For the overall cohort of infants at 29-32 weeks gestation, after the introduction of minimally invasive surfactant therapy, there were reductions in CPAP failure (epoch 1: 14%, epoch 2: 7.2%) and average days of intubation, with equivalent surfactant use and days of respiratory support (intubation + CPAP). Pneumothorax was substantially reduced (from 8.0 to 2.4%). These findings were mirrored within the subgroups reaching the severity threshold in each epoch. The incidence of bronchopulmonary dysplasia was low in both epochs.
Conclusions: Selective use of minimally invasive surfactant therapy at 29-32 weeks gestation permits a primary CPAP strategy to be pursued with a high rate of success, and a low risk of pneumothorax.
Predictors of CPAP failure after less-invasive surfactant administration in preterm infants.
Alsina-Casanova M, Brito N, Balcells-Esponera C, Herranz-Barbero A, Teresa-Palacio M, Soler-Garcia A Front Pediatr. 2024; 12:1444906.
PMID: 39258148 PMC: 11383777. DOI: 10.3389/fped.2024.1444906.
Kaleem A, Haroon F, Fatima B, Victor G, Qadir M, Waheed K Pak J Med Sci. 2023; 39(3):848-852.
PMID: 37250559 PMC: 10214821. DOI: 10.12669/pjms.39.3.7283.
Wang L, Zhang M, Yi Q Evid Based Complement Alternat Med. 2022; 2022:6225282.
PMID: 36159566 PMC: 9507732. DOI: 10.1155/2022/6225282.
Hu Z, Zhou G Comput Math Methods Med. 2022; 2022:9588740.
PMID: 36118831 PMC: 9481394. DOI: 10.1155/2022/9588740.
Baczynski M, Deekonda V, Hamilton L, Lindsay B, Ye X, Jain A Pediatr Res. 2022; 93(4):990-995.
PMID: 35854087 DOI: 10.1038/s41390-022-02197-3.